# Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein Thrombosis

Study · id `cardio:ct-nct04967573` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04967573](<https://clinicaltrials.gov/study/NCT04967573>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04967573

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 480 participants.

## Technical summary

Registry record NCT04967573. Randomized; triple masking; primary purpose treatment. Start 2021-08-01 (actual); primary completion 2023-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 480 participants (planned count; ClinicalTrials.gov record NCT04967573, source copy `cardio:ctgov-nct04967573-2022-02-16`, retrieved 2026-10-31)
- Started: 2021-08-01 (actual) (ClinicalTrials.gov record NCT04967573, source copy `cardio:ctgov-nct04967573-2022-02-16`, retrieved 2026-10-31)
- Primary completion: 2023-06-30 (anticipated) (ClinicalTrials.gov record NCT04967573, source copy `cardio:ctgov-nct04967573-2022-02-16`, retrieved 2026-10-31)
- Completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT04967573, source copy `cardio:ctgov-nct04967573-2022-02-16`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04967573, source copy `cardio:ctgov-nct04967573-2022-02-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04967573-2022-02-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Prophylactic vs Therapeutic Anticoagulation in Symptomatic Isolated Distal Deep Vein Thrombosis
- Condition: Venous Thrombosis
- Intervention (Drug): Rivaroxaban
- Lead sponsor: Shanghai Zhongshan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: Shanghai Zhongshan Hospital (`cardio:org-shanghai-zhongshan-hospital`)

## Provenance

Content hash: 88dc4eaa4d2d899a248bdd2654a013e31e940d422209ee8833a74de729e0e10f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
